Role of receptor tyrosine kinases mediated signal transduction pathways in tumor growth and angiogenesis—New insight and futuristic vision
In the past two decades, significant progress has been made in the past two decades
towards the understanding of the basic mechanisms underlying cancer growth and …
towards the understanding of the basic mechanisms underlying cancer growth and …
[HTML][HTML] Pleckstrin Homology [PH] domain, structure, mechanism, and contribution to human disease
G Powis, EJ Meuillet, M Indarte, G Booher… - Biomedicine & …, 2023 - Elsevier
The pleckstrin homology [PH] domain is a structural fold found in more than 250 proteins
making it the 11th most common domain in the human proteome. 25% of family members …
making it the 11th most common domain in the human proteome. 25% of family members …
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
JA Dubovsky, KA Beckwith, G Natarajan… - Blood, The Journal …, 2013 - ashpublications.org
Given its critical role in T-cell signaling, interleukin-2–inducible kinase (ITK) is an appealing
therapeutic target that can contribute to the pathogenesis of certain infectious, autoimmune …
therapeutic target that can contribute to the pathogenesis of certain infectious, autoimmune …
Practice parameter for the diagnosis and management of primary immunodeficiency
FA Bonilla, DA Khan, ZK Ballas, J Chinen… - Journal of Allergy and …, 2015 - Elsevier
The American Academy of Allergy, Asthma & Immunology (AAAAI) and the American
College of Allergy, Asthma & Immunology (ACAAI) have jointly accepted responsibility for …
College of Allergy, Asthma & Immunology (ACAAI) have jointly accepted responsibility for …
Non-receptor protein tyrosine kinases signaling pathways in normal and cancer cells
Protein tyrosine kinases (PTKs) are enzymes that transfer phosphate groups to tyrosine
residues on protein substrates. Phosphorylation of proteins causes changes in their function …
residues on protein substrates. Phosphorylation of proteins causes changes in their function …
[HTML][HTML] Interleukin-2-inducible T-cell kinase (ITK) deficiency-clinical and molecular aspects
S Ghosh, K Bienemann, K Boztug… - Journal of Clinical …, 2014 - Springer
In patients with underlying immunodeficiency, Epstein-Barr virus (EBV) may lead to severe
immune dysregulation manifesting as fatal mononucleosis, lymphoma, lymphoproliferative …
immune dysregulation manifesting as fatal mononucleosis, lymphoma, lymphoproliferative …
PI3K and STAT3: a new alliance
PK Vogt, JR Hart - Cancer discovery, 2011 - AACR
Recent proteomic data have uncovered an interdependence of PI3K (phosphatidylinositol 3-
kinase) and STAT3. In PI3K-transformed murine cells, STAT3 is phosphorylated on Y705 …
kinase) and STAT3. In PI3K-transformed murine cells, STAT3 is phosphorylated on Y705 …
The Bruton tyrosine kinase (BTK) inhibitor PCI‐32765 synergistically increases proteasome inhibitor activity in diffuse large‐B cell lymphoma (DLBCL) and mantle cell …
G Dasmahapatra, H Patel, P Dent… - British journal of …, 2013 - Wiley Online Library
Interactions between the Bruton tyrosine kinase (BTK) inhibitor PCI‐32765 and the
proteasome inhibitor (bortezomib) were examined in diffuse large‐B cell lymphoma …
proteasome inhibitor (bortezomib) were examined in diffuse large‐B cell lymphoma …
Blockade of interleukin-2-inducible T-cell kinase signaling attenuates acute lung injury in mice through adjustment of pulmonary Th17/Treg immune responses and …
Acute lung injury (ALI) is linked with considerable morbidity and mortality. ALI can be caused
by various agents, one of them being sepsis. ALI is characterized by injury to vascular …
by various agents, one of them being sepsis. ALI is characterized by injury to vascular …
[HTML][HTML] Addition of BTK inhibitor orelabrutinib to rituximab improved anti-tumor effects in B cell lymphoma
H Yu, X Wang, J Li, Y Ye, D Wang, W Fang, L Mi… - Molecular Therapy …, 2021 - cell.com
Bruton tyrosine kinase (BTK) inhibitor ibrutinib has been validated as an effective drug to
treat B cell malignancies. Combined therapies comprising ibrutinib and anti-CD20 …
treat B cell malignancies. Combined therapies comprising ibrutinib and anti-CD20 …